Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Division of Infectious Diseases, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Department of Infection Control, Taipei Medical University Hospital, Taipei, Taiwan.
J Microbiol Immunol Infect. 2023 Apr;56(2):337-343. doi: 10.1016/j.jmii.2022.08.017. Epub 2022 Sep 28.
BACKGROUND/PURPOSE: The rapid emergence of Pseudomonas aeruginosa resistance made selecting antibiotics more challenge. Antimicrobial stewardship programs (ASPs) are urging to implant to control the P. aeruginosa resistance. The purpose of this study is to evaluate the relationship between antimicrobial consumption and P. aeruginosa resistance, the impact of ASPs implemented during the 14-year study period.
A total 14,852 P. aeruginosa isolates were included in our study. The resistant rate and antimicrobial consumption were investigated every six months. Linear regression analysis was conducted to examine the trends in antibiotics consumption and antimicrobial resistance over time. The relationship between P. aeruginosa resistance and antimicrobial consumption were using Pearson correlation coefficient to analysis. The trend of resistance before and after ASPs implanted is evaluated by segment regression analysis.
P. aeruginosa resistance to ceftazidime, gentamicin, amikacin, ciprofloxacin and levofloxacin significantly decreased during the study period; piperacillin/tazobactam (PTZ), cefepime, imipenem/cilastatin and meropenem remained stable. The P. aeruginosa resistance to ciprofloxacin and levofloxacin increasing initial then decreased after strictly controlled the use of levofloxacin since 2007. As the first choice antibiotic to treat P. aeruginosa, the consumption and resistance to PTZ increase yearly and resistance became stable since extended-infusion therapy policy implant in 2009.
Our ASP intervention strategy, which included extended infusion of PTZ and restrict use of levofloxacin, may be used to control antimicrobial resistance of P. aeruginosa in medical practice.
背景/目的:铜绿假单胞菌耐药性的迅速出现使得抗生素的选择更加具有挑战性。抗菌药物管理计划(ASPs)正在敦促植入以控制铜绿假单胞菌耐药性。本研究的目的是评估抗菌药物消耗与铜绿假单胞菌耐药性之间的关系,以及在 14 年研究期间实施 ASP 的影响。
本研究共纳入了 14852 株铜绿假单胞菌分离株。每六个月调查一次耐药率和抗菌药物消耗。线性回归分析用于研究抗生素消耗和抗菌药物耐药性随时间的变化趋势。使用皮尔逊相关系数分析铜绿假单胞菌耐药性与抗菌药物消耗之间的关系。采用分段回归分析评估 ASP 植入前后耐药趋势。
在研究期间,铜绿假单胞菌对头孢他啶、庆大霉素、阿米卡星、环丙沙星和左氧氟沙星的耐药率显著下降;哌拉西林/他唑巴坦(PTZ)、头孢吡肟、亚胺培南/西司他丁和美罗培南保持稳定。自 2007 年严格控制左氧氟沙星的使用以来,铜绿假单胞菌对环丙沙星和左氧氟沙星的耐药性先增加后减少。PTZ 作为治疗铜绿假单胞菌的首选抗生素,其消耗量和耐药性逐年增加,自 2009 年延长输注疗法政策实施以来,耐药性趋于稳定。
我们的 ASP 干预策略,包括延长 PTZ 的输注和限制左氧氟沙星的使用,可能用于控制医疗实践中铜绿假单胞菌的抗菌药物耐药性。